Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Treatment of Ruptured Intracranial Aneurysms in China.

2. Oktober 2018 aktualisiert von: He xuying, Zhujiang Hospital

The Safety and Efficacy of Ruptured Intracranial Aneurysms Embolized Assisted With Stents（SERIAES）.

Ruptured intracranial aneurysms is currently a common disease that seriously affects human health and quality of life due to its high morbidity,high mortality and high disability. At present,Ruptured intracranial aneurysms are treated with craniotomy clipping and interventional embolization ,but for ruptured wide-neck intracranial aneurysms, the treatment of craniotomy clipping and coiling embolization are not effective.With the improvement of endovascular treatment materials and techniques, three dimensional coil basket technique, double microcatheter technique, balloon assisted ONYX embolization, simple stent covered aneurysm neck, balloon or stent assisted neck remodeling and coil embolization are used in endovascular treatment of ruptured wide-neck intracranial aneurysms. The treatment methods are different in the intervention effect of ruptured wide-neck intracranial aneurysms, for example, the complications of interventional therapy are lower than craniotomy clipping,but the rate of well functional outcome (mRS ≤2) differed significantly by 3 months follow-up (65.0% vs.75.0%), and there is not standard of treatment in different parts of ruptured wide-neck intracranial aneurysms in our country, the choice of interventional therapy or craniotomy clipping are different in different clinical centers; on the other hand, there are serious problems in the treatment of ruptured wide-neck intracranial aneurysms, because without the relevant guidelines of diagnosis and treatment of ruptured wide-neck intracranial aneurysms, different clinical centers will cause excessive treatment of ruptured wide-neck intracranial aneurysms, not only bring unreasonable utilization of medical resources, but also cause the subject's life and property to be threatened.

The patients with ruptured wide-neck intracranial aneurysms(n=1084) and unruptured intracranial aneurysms(n=300) were included in prospective cohort study, after interventional therapy and craniotomy clipping, setting fixed time for postoperative follow-up, the clinical data and image data were recorded, the safety, efficacy and economic benefits of interventional treatment and craniotomy clipping were compared, providing strategies for the standardized treatment of ruptured wide-neck intracranial aneurysms.

Studienübersicht

Status

Unbekannt

Bedingungen

Detaillierte Beschreibung

For this study, investigators consulted and hired professionals and experts about data collection, data and methodology, including Data Monitoring Committee, Data Management Committee, Project Academic Committee,Executive Group Project Manager, Project Statistician, Technical Support Center, investigators have a scientific regulations for this project, Project Manager and Executive Group: To ensure the successfully implementation of this project, including charging the daily operations of the study in 6 different research hospitals, organizing the monthly meeting to consider issues raised during the monthly progress of the study, liaising with the steering committee the data management center and statistical center , Data management Committee: To be responsible for setting up and maintain the Electronic Data Capture(EDC) System according to the paper case Report Form (pCRF) designed by principal investigators. To collect and save the pCRF coming from sub-centers. To entry the data into EDC system and keep the same with CRF. To organize training for the investigators about the rules in filling the EDC and pCRF.To determine the frequency of the Data Management Report and to fed it back to the steering committee every three months, Data Monitoring Committee: To determine the frequency of the data monitoring including the source data(Medical records) accuracy, completeness and representativeness comparing the external data(EDC,pCRF） in 12 centers.To report the results after the monitoring back to the steering committee about the missing data, non-reported and other problems about the study. To make a Standard Operation Procedure (SOP) from getting data to using data. Academic Committee: To supervise the academic issues including patient recruitment, protocol deviation, adverse events evaluating. To settle down the question and problem in the process of the study, Project Statistician: We cooperate with the Statisticians of Medical Research & Biometrics center National Center for Cardiovascular Diseases, China ti get the professional statistical report. Technical Support Center: To provide technical support during the process of the study.

Studientyp

Beobachtungs

Einschreibung (Voraussichtlich)

1384

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • China
    • Guangdong
      • Guangzhou, Guangdong, China, 510282
        • Southern medical university, zhujiang hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

14 Jahre und älter (Kind, Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Patients with ruptured intracranial aneurysms and un-ruptured intracranial aneurysms.

Beschreibung

Inclusion Criteria:

  1. At least one imaging methods( CTA/ MRA/DSA ) confirmed ruptured wide-neck intracranial aneurysms (fundus-to-neck ratio < 2 or neck diameter > 4 mm );
  2. Stent-Assisted Coiling of un-ruptured intracranial aneurysms, whether have clinical symptoms or no;
  3. For multiple aneurysms, regardless of previous treatment, the requirement for treatment interval should >6 months;
  4. The subjects age 14 years;
  5. subjects or family members agree to sign informed consent.

Exclusion Criteria:

  1. Subjects with other intracranial vascular malformations, such as AVM, AVF. Etc;
  2. Subjects with malignant tumors in the intracranial or other parts of the body;
  3. Fusiform, traumatic, bacterial or dissecting aneurysm;
  4. Subjects with severe mental illness unable to communicate when diagnosing disease;
  5. The body condition is poor, the survival time is less than 1 year or poor physical condition, cannot tolerate the general anesthesia or aneurysm surgery;
  6. Subjects involved in other intracranial aneurysms related clinical research;
  7. A patient who received surgical clipping or endovascular treatment at once;
  8. Subjects who were not followed up；

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
The safety evaluation of interventional therapy and craniotomy clipping.
Zeitfenster: 6 months later after operation.
2.The safety evaluation including the mortality(mRS=6) rate and disability(3<mRS<6) rate of subjects.
6 months later after operation.
The safety evaluation of interventional therapy and craniotomy clipping.
Zeitfenster: 6 months later after operation.
The safety evaluation including the mortality(mRS=6) rate of subjects.
6 months later after operation.
Modified Rankin score ( mRS ).
Zeitfenster: 1 year.

0. completely silent.

  1. despite symptoms, but not visibly disabled, can complete all regular duties and activities
  2. mild disabilities, not all activities previously possible, but can deal with personal affairs without need of assistance
  3. moderate disability requires some help, but walking does not need assistance
  4. severe disabilities, unable to walk independently, no others can not meet their needs
  5. severely disabled, bedridden, Urine, requiring continuous care and care
  6. mortality.
1 year.
Raymond classification.
Zeitfenster: 1 year.
  1. Complete occlusion
  2. Partial occlusion
  3. Recurrence.
1 year.
The effectiveness evaluation of craniotomy clipping.
Zeitfenster: 6 months later after operation.
The effectiveness evaluation including the complete occlusion( Raymond classification=1) rate of aneurysms.
6 months later after operation.
The effectiveness evaluation of interventional treatment.
Zeitfenster: 6 months later after operation.
The effectiveness evaluation including the recurrence ( Raymond classification =3) rate of aneurysms.
6 months later after operation.
The effectiveness evaluation of craniotomy clipping.
Zeitfenster: 6 months later after operation.
The effectiveness evaluation including the recurrence( Raymond classification=3) rate of aneurysms.
6 months later after operation.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
The safety evaluation interventional therapy.
Zeitfenster: 12 months later after operation.
The safety evaluation including the mortality( mRS=6)rate and disability(3<mRS<6 ) rate of subjects.
12 months later after operation.
The effectiveness evaluation of interventional treatment.
Zeitfenster: 12 months later after operation.
The effectiveness evaluation including the complete occlusion( Raymond classification=1 ) rate of aneurysms.
12 months later after operation.
The success rate of treatment.
Zeitfenster: 6 months later after operation.
Angiography revealed total or near total occlusion of aneurysm in 6 months after operation, no recurrence of aneurysm was found. the treatment was considered successful.
6 months later after operation.
The incidence of major adverse events after 3 months of surgery.
Zeitfenster: 3 months.
3 months.
The incidence of major adverse events in 3 months and 6 months later after operation.
Zeitfenster: 3 months and 6 months later after operation.
3 months and 6 months later after operation.
The incidence of major adverse events in 6 months and 12 months later after operation.
Zeitfenster: 6 months and 12 months later after operation.
6 months and 12 months later after operation.
The safety evaluation of craniotomy clipping.
Zeitfenster: 12 months later after operation.
The safety evaluation including the mortality( MRS=6 ) rate and disability(3<MRS <6) rate of subjects.
12 months later after operation.
The effectiveness evaluation of interventional treatment.
Zeitfenster: 12 months later after operation.
The effectiveness evaluation including the recurrence( Raymond classification=3 ) rate of aneurysms.
12 months later after operation.
The effectiveness evaluation of craniotomy clipping.
Zeitfenster: 12 months later after operation.
The effectiveness evaluation including the complete occlusion( Raymond classification=1 ) rate of aneurysms.
12 months later after operation.
The effectiveness evaluation of craniotomy clipping.
Zeitfenster: 12 months later after operation.
The effectiveness evaluation including the recurrence( Raymond classification=3) rate of aneurysms.
12 months later after operation.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Zhujiang Hospital

Mitarbeiter

Second Affiliated Hospital, School of Medicine, Zhejiang University
Xuanwu Hospital, Beijing
The First Affiliated Hospital of Zhengzhou University
Air Force Military Medical University, China
First Affiliated Hospital of Wenzhou Medical University
Second Affiliated Hospital of Nanchang University
First Affiliated Hospital of Harbin Medical University

Ermittler

  • Hauptermittler: Xuying He, PH. D, Study Principal Investigator Department of Neurosurgery, Southern Medical University, Zhujiang Hospital

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Voraussichtlich)

1. November 2018

Primärer Abschluss (Voraussichtlich)

31. Mai 2020

Studienabschluss (Voraussichtlich)

31. Mai 2020

Studienanmeldedaten

Zuerst eingereicht

7. Februar 2018

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

8. März 2018

Zuerst gepostet (Tatsächlich)

12. März 2018

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

3. Oktober 2018

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

2. Oktober 2018

Zuletzt verifiziert

1. Oktober 2018

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • 2016YFC1300800

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

investigators can share the original data 5 years after the study

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren